Oppenheimer Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $277
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Trevor Allred maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $275 to $277.
Oppenheimer analyst Trevor Allred maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $275 to $277.